Inotiv, Inc. to Participate in Three Investor Conferences in September 2025
Inotiv (NASDAQ:NOTV), a leading contract research organization focused on nonclinical drug discovery services and research models, announced its participation in three upcoming investor conferences in September 2025.
CEO Robert Leasure Jr. and CFO Beth Taylor will attend the H.C. Wainwright Global Investment Conference (September 10), the Baird Global Healthcare Conference (September 9), and the Lake Street Capital Markets Best Ideas Growth Conference (September 11). All events will take place in New York, NY, featuring presentations and one-on-one meetings with institutional investors.
Inotiv (NASDAQ:NOTV), una delle principali organizzazioni di ricerca a contratto specializzata in servizi di scoperta di farmaci non clinici e modelli di ricerca, ha annunciato la sua partecipazione a tre conferenze per investitori previste per settembre 2025.
Il CEO Robert Leasure Jr. e la CFO Beth Taylor parteciperanno all'H.C. Wainwright Global Investment Conference (10 settembre), al Baird Global Healthcare Conference (9 settembre) e al Lake Street Capital Markets Best Ideas Growth Conference (11 settembre). Tutti gli eventi si terranno a New York, NY, e comprenderanno presentazioni e incontri one-to-one con investitori istituzionali.
Inotiv (NASDAQ:NOTV), una destacada organización de investigación por contrato centrada en servicios de descubrimiento preclínico y modelos de investigación, anunció su participación en tres próximas conferencias para inversores en septiembre de 2025.
El CEO Robert Leasure Jr. y la CFO Beth Taylor asistirán a la H.C. Wainwright Global Investment Conference (10 de septiembre), a la Baird Global Healthcare Conference (9 de septiembre) y a la Lake Street Capital Markets Best Ideas Growth Conference (11 de septiembre). Todos los eventos se celebrarán en Nueva York, NY, y contarán con presentaciones y reuniones individuales con inversores institucionales.
Inotiv (NASDAQ:NOTV)는 비임상 신약 발견 서비스와 연구 모델을 제공하는 선도적인 계약연구기관(CRO)으로, 2025년 9월에 열리는 3개의 투자자 콘퍼런스에 참가한다고 발표했습니다.
CEO 로버트 리저 주니어(Robert Leasure Jr.)와 CFO 베스 테일러(Beth Taylor)가 H.C. Wainwright Global Investment Conference(9월 10일), Baird Global Healthcare Conference(9월 9일), Lake Street Capital Markets Best Ideas Growth Conference(9월 11일)에 참석합니다. 모든 행사는 뉴욕, NY에서 열리며 발표와 기관투자가 대상 일대일 미팅이 진행됩니다.
Inotiv (NASDAQ:NOTV), une organisation de recherche sous contrat (CRO) de premier plan spécialisée dans les services de découverte de médicaments non cliniques et les modèles de recherche, a annoncé sa participation à trois conférences investisseurs en septembre 2025.
Le PDG Robert Leasure Jr. et la directrice financière Beth Taylor assisteront à la H.C. Wainwright Global Investment Conference (10 septembre), à la Baird Global Healthcare Conference (9 septembre) et à la Lake Street Capital Markets Best Ideas Growth Conference (11 septembre). Tous les événements auront lieu à New York, NY, et comprendront des présentations et des rencontres en tête-à-tête avec des investisseurs institutionnels.
Inotiv (NASDAQ:NOTV), ein führender Auftragsforschungsanbieter mit Schwerpunkt auf nichtklinischen Wirkstoffforschungsdiensten und Forschungsmodellen, gab seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2025 bekannt.
CEO Robert Leasure Jr. und CFO Beth Taylor werden an der H.C. Wainwright Global Investment Conference (10. September), der Baird Global Healthcare Conference (9. September) und der Lake Street Capital Markets Best Ideas Growth Conference (11. September) teilnehmen. Alle Veranstaltungen finden in New York, NY, statt und umfassen Präsentationen sowie Einzelgespräche mit institutionellen Investoren.
- None.
- None.
WEST LAFAYETTE, Ind., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming H.C. Wainwright 27th Annual Global Investment Conference, the Baird Global Healthcare Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference.
Conference Details
Event: Baird Global Healthcare Conference
Location: New York, NY
Date and Presentation Time: 12:50 PM Eastern Time on September 9, 2025
Event Format: Presentations and 1-on-1 meetings
Link to Webcast
Event: H.C. Wainwright 27th Annual Global Investment Conference
Location: New York, NY
Date and Presentation Time: 12:30 PM Eastern Time on September 10, 2025
Event Format: Presentations and 1-on-1 meetings
Link to Webcast
Event: Lake Street Capital Markets 9th Annual Best Ideas Growth Conference
Location: New York, NY
Date: September 11, 2025
Event format: 1-on-1 institutional investor meetings only
To schedule a meeting at the conferences with Inotiv management or for more conference information, please contact your institutional sales representative at each firm.
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.
This release and our investor presentations may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, statements regarding our intent, belief or current expectations with respect to our strategic plans; trends in the demand for our services and products; trends in the industries that consume our services and products; market and company-specific impacts of non-human primate supply and demand matters; compliance with the Resolution Agreement and Plea Agreement and the expected impacts on the Company related to the compliance plan and compliance monitor, and the expected amounts, timing and expense treatment of cash payments and other investments thereunder; our ability to service our outstanding indebtedness and to comply or regain compliance with financial covenants, including those established by the Seventh Amendment to our Credit Agreement; our current and forecasted cash position; our ability to make capital expenditures, fund our operations and satisfy our obligations; our ability to manage recurring and unusual costs; our ability to execute on and realize the expected benefits related to our restructuring and site optimization plans; our expectations regarding the volume of new bookings, pre-sales, pricing, cost savings initiatives, expansion of services, operating income or losses and liquidity; our ability to effectively fill the recent expanded capacity or any future expansion or acquisition initiatives undertaken by us; our ability to develop and build infrastructure and teams to manage growth and projects; our ability to continue to retain and hire key talent; our ability to market our services and products under our corporate name and relevant brand names; our ability to develop new services and products; our ability to negotiate amendments to the Credit Agreement or obtain waivers related to the financial covenants defined within the Credit Agreement; the potential outcome of litigation against us, including any settlement and amounts accrued or recoverable; and the impact of macroeconomic factors, including but not limited to tariffs, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission. Further discussion of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in our Annual Report on Form 10-K as filed on December 4, 2024, as well as other filings we make with the Securities and Exchange Commission.
| Company Contact | Investor Relations | |
| Inotiv, Inc. | LifeSci Advisors | |
| Beth A. Taylor, Chief Financial Officer | Steve Halper | |
| (765) 497-8381 | (646) 876-6455 | |
| beth.taylor@inotiv.com | shalper@lifesciadvisors.com |
FAQ
When and where will Inotiv (NOTV) present at the Baird Global Healthcare Conference 2025?
What is the format of Inotiv's participation at the Lake Street Capital Markets Conference 2025?
Who will represent Inotiv (NOTV) at the September 2025 investor conferences?
What time is Inotiv's presentation at the H.C. Wainwright Conference 2025?
